Highlights Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Market Closed - Nasdaq Other stock markets 01:30:00 16/05/2024 am IST			5-day change	1st Jan Change
9.24 ^USD	+13.65%		+15.64%	+186.07%

15/05	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating	MT
15/05	Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sector Update: Health Care Stocks Rise Pre-Bell Wednesday	15/05	MT
Sector Update: Health Care	15/05	MT
Arcutis Biotherapeutics Q1 Loss Narrows as Revenue Surges; Shares Soar Premarket	15/05	MT
Arcutis Biotherapeutics Q1 Loss Narrows, Revenue Increases; Shares Jump	15/05	MT
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q1 Revenue $49.6M	15/05	MT
Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes	10/04	CI
Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting	11/03	CI
Arcutis Plans $150 Million Offering, Signs Collaboration, Licensing Deal for Roflumilast in Japan; Shares Fall After Hours	29/02	MT
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Posts Q4 Revenue $13.5M, vs. Street Est of $11.4M	27/02	MT
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02	CI
Arcutis Biotherapeutics, Inc. Announces Publication of Positive Results from the Pivotal Phase 3 Trial Evaluating ZORYVE (roflumilast) Foam	29/01	CI
Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids	14/01	CI
Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii	14/01	CI
Exchange-Traded Funds Mixed; US Equities Rise Pre-Bell Monday as Investors Hope for Federal Reserve Rate Cuts Soon	18/12	MT
Arcutis Biotherapeutics Gets FDA Approval for Seborrheic Dermatitis Treatment -- Shares Surge Premarket	18/12	MT
US FDA approves Arcutis' drug to treat chronic skin disease	16/12	RE
FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older	16/12	CI
Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6	29/11	CI
Earnings Flash (ARQT) ARCUTIS BIOTHERAPEUTICS Reports Q3 Revenue $38.1M, vs. Street Est of $30.8M	03/11	MT
Arcutis Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Highlights

Filters